Cantor Fitzgerald Thinks Neos Therapeutics’ Stock is Going to Recover

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Neos Therapeutics (NEOS), with a price target of $20. The company’s shares opened today at $2.64, close to its 52-week low of $2.27.

Chen observed:

“. Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month PT of $20 for NEOS shares. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think continued success with the sales of its key drugs (Adzenys XR-ODT, Cotempla XR- ODT and Adzenys ER) as well as pipeline advancements (NT-0400 and NT-0501) will drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher.”

According to, Chen is a 5-star analyst with an average return of 16.1% and a 44.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

Neos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $14.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.69 and a one-year low of $2.27. Currently, Neos Therapeutics has an average volume of 362.6K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEOS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30,1994 and is headquartered in Grand Prairie, TX.